Henry Meds vs LifeMD: Subscription vs Compounded GLP-1

You are reading part of the PlexusDx Education Hub, where we cover GLP-1 therapy, weight management protocols, and the genetics that quietly steer metabolic outcomes. Browse all Peptides & GLP-1 education

This review is independent. PlexusDx has no business relationship with Henry Meds or LifeMD, uses no affiliate links, and earns nothing from naming either brand.

Full head-to-head: PlexusDx vs Henry Meds →

The "Henry Meds vs LifeMD" search often comes from someone deciding between a focused compounding program and a wide-scope subscription clinic. Below we contrast their models, the levers behind pricing, and the genetic dimension neither addresses. The 2026 telehealth market holds dozens of GLP-1 options; this comparison keeps to the two in the query.

The two models side by side

Henry Meds is built around telehealth paired with compounded dispensing, while LifeMD operates as a broader subscription telehealth service spanning many conditions. That difference in scope shapes everything downstream — how prescriptions route, how memberships are billed, and how weight management fits into the wider offering.

How LifeMD is organized

LifeMD runs on subscription telehealth. Medication options, program tiers, and rates vary and change, so check LifeMD's official website for the current structure whenever you evaluate it.

How Henry Meds is organized

Henry Meds pairs virtual evaluation with a compounding-pharmacy pathway. A provider issues the prescription after intake, routing either brand-name FDA-approved GLP-1 products or compounded semaglutide and tirzepatide through licensed pharmacies. See Henry Meds's official website for present details.

What actually drives the monthly cost

Across GLP-1 telehealth in 2026, monthly totals commonly land somewhere between roughly $200 and $700 or more once program fees, medication, and compounded-pharmacy dispensing are counted. The spread is wide because product choice, subscription length, and whether a program dispenses brand or compounded formulations all move the number. Henry Meds and LifeMD each publish their own figures; rather than restate a rate that may already be outdated, verify the current price on each brand's own page before committing.

The clinical evidence sits with the molecule

Whichever platform prescribes, the pharmacology comes from the compound. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide influence appetite, satiety, and gastric emptying. The trial record backs the molecules, not the brands: STEP for semaglutide in weight management (NEJM 2021), SURMOUNT for tirzepatide (NEJM 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM 2024). Results differ by dose, compound, and individual.

The inherited context both programs skip

Neither a Henry subscription nor a LifeMD membership examines the genetics underneath a GLP-1 response. FTO shapes fat-mass and obesity risk, MC4R sits at the center of satiety and energy balance, GLP1R encodes the receptor every GLP-1 compound binds, and TCF7L2 ties into glucose regulation and GLP-1 secretion. These are pathway-level signals rather than predictions of drug response, but they describe the terrain a clinician prescribes into. PlexusDx pairs its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with the Precision Peptide Genetic Test, which reads 14 pathways, 49 peptides, 150+ genetic insights across FTO, MC4R, and TCF7L2. Call it test before you invest: know your baseline, then talk it through with your provider.

Not affiliated: PlexusDx has no affiliation with Henry Meds or LifeMD and no commercial tie to any company reviewed here.

Related reading on PlexusDx: GLP 1 Hormone, What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist.

Disclaimer: This article is educational. PlexusDx is not affiliated with Henry Meds or LifeMD and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Prefer to see the PlexusDx side directly? Review the Weight Management Protocols or start with the Precision Peptide Genetic Test to map your GLP-1 pathway first.

Frequently Asked Questions

Is LifeMD only a weight loss service?

No. LifeMD is a broad subscription telehealth platform that covers many conditions, with weight management as one program among several. Henry Meds concentrates more narrowly on compounded GLP-1 care. Scope is a real difference: check LifeMD's own site for how weight management fits its wider membership.

Which program uses compounded medication?

Henry Meds is built around a compounding-pharmacy pathway, while LifeMD's dispensing depends on its current partners and your eligibility. Either program may route brand-name or compounded semaglutide and tirzepatide. The pharmacy pathway, not the subscription itself, determines the formulation you receive.

Can the Precision Peptide Genetic Test rank these programs for me?

No. It never predicts response to LifeMD, Henry Meds, or any compound. It reports pathway-level variants in FTO and MC4R, and TCF7L2 that describe your baseline GLP-1 biology — context that holds regardless of which subscription or clinic writes the prescription.

How is PlexusDx different from a subscription clinic?

PlexusDx dispenses semaglutide and tirzepatide through its Weight Management Protocols and layers in the Precision Peptide Genetic Test. The difference is upstream genetic context on FTO, MC4R variants, which subscription platforms like LifeMD and programs like Henry Meds do not pair with the medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education